


Helping to bring immunotherapies to cancer patients in need



Catalyst Oncology is a niche oncology CRO devoting time, energy, and capital to supporting biotechs in bringing next-generation immuno-oncology (IO) therapies to cancer patients in need. Oncology clinical research is complex, demanding, and continually evolving. Bringing effective IO therapies to proof-of-concept and then to market as fast as possible is our mission because every second counts for patients and their families living with cancer.

>40% of our active oncology portfolio is IO

- Cell therapies (CAR-T, TILs)
 - Autologous and allogeneic
 - Hematologic malignancies and solid tumors
- Bispecifics
 - T-cell and macrophage engagers
- Tumor microenvironment remodelers
- Oncolytic viruses
- Vaccines
- Gene therapies
- Novel checkpoints

WE UNDERSTAND
the nuances of IO trials

- Complex modalities (live cells, viruses, bispecific antibodies)
- Safety/toxicity profiles (CRS, ICANS, TLS, delayed reactions)
- Novel endpoints and study designs (iRECIST, mTPI, BOIN)
- Biomarker involvement; increased data collection
- Coordination of numerous vendors

19+ years
serving small
to mid-sized
biotechs

Exclusively Biotech-Focused

Built to work exclusively with biotechs, our flexible processes and approach allow us to listen first, align goals, and execute with an eye to rapid shifts when protocols amend or breakthrough designations move a product straight from Phase I to registration.


Seasoned Oncology Experts

With an average of 9+ years of oncology experience for key roles (PM, CTL, DM, Clinical Science, etc.), our oncology niche guarantees you a seasoned team across all functions.

A Transparent, 'People-First' Culture

We are responsive and attentive to the needs of both our customers and staff. Our industry-leading employee and project team retention guarantee program continuity, increased efficiency, and happy investigative sites.

Additional Differentiators



Active Next-Gen Oncology Experience

Working both locally and globally across Phases I-III in a range of solid tumor and hematologic indications, we understand the nuances of complex study designs, novel endpoints, and cutting-edge technologies.

